Attached files
file | filename |
---|---|
EX-99 - PRESS RELEASE - GenMark Diagnostics, Inc. | rrd341348_37514.htm |
Delaware
|
27-2053069
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
incorporation)
|
Identification No.)
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
The foregoing description of the Agreement is qualified in its entirety by reference to the actual text of the Agreement, a copy of which GenMark expects to file with its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012.
This Report includes forward-looking statements regarding events, trends and business prospects which may affect our future operating results and financial position, and such statements are subject to risks and uncertainties that could cause our actual performance, operating results and financial position to differ materially. Such forward-looking statements include, but are not limited to, statements concerning if and when definitive agreements with ALL may be negotiated and executed, the development and functionality of our products and the continued development of our technology, including in-vitro diagnostic platforms and assays, the future payment of milestone payments by the Company, the value of any securities to be purchased by Company, and the ability of the Company and its partners to manufacture products in a consistent, timely and cost-effective manner. Some of the risks and uncertainties associated with such forward-looking statements include, but are not limited to, risks related to our history of operating losses, our ability to successfully commercialize our products, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, ability to maintain gross margins, regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the 'Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
On April 5, 2012, GenMark Diagnostics, Inc. issued a press release announcing that it entered into a heads of agreement with Advanced Liquid Logic, Inc. A copy of the press release is attached as Exhibit 99.1.
GenMark Diagnostics, Inc.
|
||||||||
Date: April 05, 2012
|
By:
|
/s/ Matthew Cohen
|
||||||
Matthew R. Cohen
|
||||||||
SVP, General Counsel
|
||||||||
Exhibit No.
|
Description
|
|
EX-99.1
|
Press release
|